A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients
Lung Cancer|Camrelizumab
DRUG: Camrelizumab + chemotherapy+Thalidomide|DRUG: Camrelizumab + chemotherapy+placebo
Incidence rate of any grade Reactive Cutaneous Capillary Endothelial Proliferation(RCCEP), Incidence rate of any grade Reactive Cutaneous Capillary Endothelial Proliferation(RCCEP), 2 years
Median time to RCCEP, Median time to RCCEP, 2 years|Median time to RCCEP of level 3 or above, Median time to RCCEP of level 3 or above, 2 years|Incidence rate of ≥G3 grade RCCEP, Incidence rate of ≥G3 grade RCCEP, 2 years|Overall Response Rate (ORR), Overall Response Rate (ORR), 2 years|Progression-Free Survival (PFS), Progression-Free Survival (PFS), 2 years|Overall Survival(OS), Overall Survival(OS), 2 years|Treatment-related Adverse Events (TRAE), Treatment-related Adverse Events (TRAE), 2 years
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients